Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) Meeting Abstract


Authors: Bartlett, N. L.; Sehn, L. H.; Assouline, S. E.; Bosch, F.; Diefenbach, C. S. M.; Flinn, I.; Hong, J.; Kim, W. S.; Matasar, M. J.; Nastoupil, L. J.; Schuster, S. J.; Shadman, M.; Yoon, S. S.; Bender, B.; Kwan, A.; Cunlin, W.; Wei, M. C.; Yin, S.; Yousefi, K.; Budde, L. E.
Abstract Title: Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL)
Meeting Title: 55th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 37
Issue: 15 Suppl.
Meeting Dates: 2019 May 31-Jun 4
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2019-05-20
Start Page: 428s
Language: English
ACCESSION: WOS:000487345806280
PROVIDER: wos
Notes: Meeting Abstract: 7518 -- Source: Wos